DGAP-Adhoc
Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to some EUR 4.76 million - Seite 3
offered or sold in Australia, Canada or Japan, or to, or for the account or
benefit of, any national, resident or citizen of Australia, Canada or
Japan. The offer and sale of the securities referred to in this
announcement has not been and will not be registered under the U.S.
Securities Act or under the applicable securities laws of Australia, Canada
or Japan. There will be no public offer of the securities in the United
States.
This announcement also does not constitute a prospectus within the meaning
of the EU Directive 2003/71/EC of the European Parliament and of the
Council of 4 November 2003 as amended ("Prospectus Directive").
24-Feb-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: | English |
Company: | Elanix Biotechnologies AG |
Domstr. 22 | |
14482 Potsdam | |
Germany | |
ISIN: | DE000A0WMJQ4 |
WKN: | A0WMJQ |
Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf |
End of Announcement | DGAP News Service |
|
Lesen Sie auch
547579 24-Feb-2017 CET/CEST
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte